



Patented Medicine
Prices
Review Board
Since 1987

PMPRB COMMUNIQUÉ

The PMPRB to Hold a Public Hearing Into the Price ratio-Salbutamol HFA

OTTAWA, **July 22, 2008**: The Patented Medicine Prices Review Board will hold a public hearing commencing on January 12, 2009, in the matter of ratiopharm Inc. and the price of the patented medicine ratio-Salbutamol HFA ("ratio-Salbutamol"). A pre-hearing conference will also be held on October 27, 2008.

The purpose of the hearing is to determine whether, under sections 83 and 85 of the *Patent Act*, ratiopharm is selling or has sold the medicine known as ratio-Salbutamol in any market in Canada at a price that, in the Board's opinion, is or was excessive and if so, what order, if any, should be made.

The medicine ratio-Salbutamol is a new DIN of an existing dosage form of an existing bronchodilator medicine (salbutamol sulphate) which relieves chest tightness and wheezing caused by spasms or narrowing in the small air passages of the lungs.

Persons wishing to intervene in this proceeding are required to apply to the Board for leave to intervene **on or before September 4, 2008**. Such persons should contact the Secretary of the Board for further information on the procedure.

The Notice of Hearing in this matter and the Statement of Allegations of Board Staff are available on the PMPRB Web site under Regulatory; Hearings.

All requests for information should be addressed to the Secretary of the Board.

Sylvie Dupont
Secretary of the Patented Medicine Prices Review Board

Toll-free number: 1-877-861-2350
Direct line: (613) 954-8299
Fax: (613) 952-7626
E-mail: sdupont@pmprb-cepmb.gc.ca

The mission of the Patented Medicine Prices Review Board (PMPRB) is to protect consumer interests and contribute to Canadian health care by ensuring that prices of patented medicines are not excessive and by analyzing and reporting to Canadians on price trends of all medicines and on research and development conducted by patentees.

Canada